An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic.

Slides:

Advertisements

Similar presentations

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Advertisements

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Clinical Lymphoma, Myeloma and Leukemia

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management Jorge E. Cortes, Carlos.

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis Meletios Athanasios.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry ( ) Sundar Jagannath, Rafat Abonour, Brian.

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

Multiple Myeloma: Diagnosis and Treatment

Current Therapy for Multiple Myeloma

William L. Lanier, MD Mayo Clinic Proceedings

Volume 16, Issue 13, Pages (October 2015)

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma Vincent L. Hansen, Morton.

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for.

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan,

A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease Garret Cullen, Denise Keegan, Hugh.

Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective,

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML Benyam Muluneh, Kaitlyn Buhlinger,

Grövdal M et al. Blood 2008;112:Abstract 223.

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Isaac M. Bromberg, MD Journal of Pain and Symptom Management

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic.

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma Shumaila.

Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen–Mismatched Stem Cell Microtransplantation Improved Outcomes.

Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature

Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML)

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075) Juan C. Ramos, Joseph A. Sparano,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Nicholas E. Khan, Philip S. Rosenberg, Blanche P. Alter

Pradnya Chopade, Luke P. Akard Clinical Lymphoma, Myeloma and Leukemia

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Clinical Lymphoma, Myeloma and Leukemia

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid.

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Large-Cell Transformation of Mycosis Fungoides Occurring at the Site of Previously Treated Cutaneous B-Cell Lymphoma Jennifer L. Herrmann, Naveed Sami

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Clinical Lymphoma, Myeloma and Leukemia

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse:

Autologous Stem Cell Transplantation for POEMS Syndrome

Presentation transcript:

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices Esprit Ma, Vijayveer Bonthapally, Anita Chawla, Patrick Lefebvre, Ronan Swords, Marie-Hélène Lafeuille, Jonathan Fortier, Bruno Emond, Mei Sheng Duh, Bruce J. Dezube Clinical Lymphoma, Myeloma and Leukemia Volume 16, Issue 11, Pages 625-636.e3 (November 2016) DOI: 10.1016/j.clml.2016.08.006 Copyright © 2016 The Author(s) Terms and Conditions

Figure 1 Disposition of Elderly Patient With AML. Altos Solutions (November 2005-February 2014). aTreatment Included Arsenic Trioxide, Azacitidine, Bortezomib, Cyclophosphamide, Cytarabine, Decitabine, Dexamethasone, Daunorubicin, Docetaxel, Doxorubicin, Epirubicin, Idarubicin, Methotrexate, Mitoxantrone, Rituximab, and Tretinoin. bCategory per Earlier NCCN Guidelines Recommendations.36 cSeven Days Cytarabine 100-200 mg/m2 With 7 Days Idarubicin 12 mg/m2, or 3 Days Daunorubicin 45-90 mg/m2, or 3 Days Mitoxantrone 12 mg/m2 Abbreviations: AML = acute myeloid leukemia; HU = hydroxyurea; NCCN = National Comprehensive Cancer Network. Clinical Lymphoma, Myeloma and Leukemia 2016 16, 625-636.e3DOI: (10.1016/j.clml.2016.08.006) Copyright © 2016 The Author(s) Terms and Conditions

Figure 2 Overall Survival From (A) AML Diagnosis, (B) First AML Treatment Abbreviations: AML = acute myeloid leukemia; BSC = best supportive care; HU = hydroxyurea; NR = not reached. Clinical Lymphoma, Myeloma and Leukemia 2016 16, 625-636.e3DOI: (10.1016/j.clml.2016.08.006) Copyright © 2016 The Author(s) Terms and Conditions